LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma. Issue 26 (30th June 2022)

• Record Type: Journal Article
• Authors: Yu, Ge; Mu, Han; Fang, Feng; Zhou, Hongyuan; Li, Huikai; Wu, Qiang; Xiong, Qingqing; Cui, Yunlong
• Is Part Of: Medicine. Volume 101:Issue 26(2022)
• Page Start: e29763
• Publication Date: 2022-06-30
• Subjects: liver hepatocellular carcinoma -- LRP1B mutation -- prognosis -- tumor mutation burden; Medicine -- Periodicals; Medicine -- Periodicals; Médecine -- Périodiques; Geneeskunde; Medicine; Periodicals; Periodicals; 610.5
• DOI: 10.1097/MD.0000000000029763
• Languages: English
• ISSNs: 0025-7974

Abstract

Abstract : Background: Liver hepatocellular carcinoma (LIHC) is the most common primary liver cancer and the main cause of death in patients with cirrhosis. LRP1B is found to involve in a variety of cancers, but the association of LRP1B mutation with tumor mutation burden (TMB) and prognosis of LIHC is rarely studied. Methods and Results: Herein, we analyzed the somatic mutation data of 364 LIHC patients from The Cancer Genome Atlas (TCGA) and found that LRP1B showed elevated mutation rate. Calculation of the TMB in LRP1B mutant and LRP1B wild-type groups showed that LRP1B mutant group had higher TMB compared with that in LRP1B wild-type group. Then survival analysis was performed and the survival curve showed that LRP1B mutation was associated with poor survival outcome, and this association remained to be significant after adjusting for multiple confounding factors including age, gender, tumor stage, mutations of BRCA1, BRCA2, and POLE. Conclusion: Collectively, our results revealed that LRP1B mutation was related to high TMB value and poor prognosis in LIHC, indicating that LRP1B mutation is probably helpful for the selection of immunotherapy and prognosis prediction in LIHC.